Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Sreeneeranj Kasichayanula(Gilead Sciences (United States)), David W. Boulton(AstraZeneca (Poland)), Steven C. Griffen(Io Therapeutics (United States)), Frank LaCreta(Fox Chase Cancer Center), Xiaoni Liu(Bristol-Myers Squibb (Germany))
Cited by 277
Related Papers
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k
Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State
|The Journal of Clinical Endocrinology & Metabolism|2007|373
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295